Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 12/2013

01-12-2013 | Original Research Paper

Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure

Authors: Yu-long Luo, Pei-bo Li, Chen-chen Zhang, Yan-fang Zheng, Sheng Wang, Yi-chu Nie, Ke-jian Zhang, Wei-wei Su

Published in: Inflammation Research | Issue 12/2013

Login to get access

Abstract

Objective

The effects of four antitussives, including codeine phosphate (CP), moguisteine, levodropropizine (LVDP) and naringin, on airway neurogenic inflammation and enhanced cough were investigated in guinea pig model of chronic cough.

Methods

Guinea pigs were exposed to CS for 8 weeks. At the 7th and 8th week, the animals were treated with vehicle, CP (4.8 mg/kg), moguisteine (24 mg/kg), LVDP (14 mg/kg) and naringin (18.4 mg/kg) respectively. Then the cough and the time-enhanced pause area under the curve (Penh-AUC) during capsaicin challenge were recorded. The substance P (SP) content, NK-1 receptor expression and neutral endopeptidase (NEP) activity in lung were determined.

Results

Chronic CS exposure induced a bi-phase time course of cough responsiveness to capsaicin. Eight weeks of CS exposure significantly enhanced the airway neurogenic inflammation and cough response in guinea pigs. Two weeks of treatment with CP, moguisteine, LVDP or naringin effectively attenuated the chronic CS-exposure enhanced cough. Only naringin exerted significant effect on inhibiting Penh-AUC, SP content and NK-1 receptor expression, as well as preventing the declining of NEP activity in lung.

Conclusions

Chronic CS-exposed guinea pig is suitable for studying chronic pathological cough, in which naringin is effective on inhibiting both airway neurogenic inflammation and enhanced cough.
Literature
1.
Reynolds SM, Mackenzie AJ, Spina D, Page CP. The pharmacology of cough. Trends Pharmacol Sci. 2004;25:569–76.CrossRefPubMed
2.
3.
De Swert KO, Joos GF. Extending the understanding of sensory neuropeptides. Eur J Pharmacol. 2006;533:171–81.CrossRefPubMed
4.
Sekizawa K, Jia YX, Ebihara T, Hirose Y, Hirayama Y, Sasaki H. Role of substance P in cough. Pulm Pharmacol. 1996;9:323–8.CrossRefPubMed
5.
Bergren DR. Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs. Respir Physiol. 2001;126:127–40.CrossRefPubMed
6.
Lewis CA, Ambrose C, Banner K, Battram C, Butler K, Giddings J, et al. Animal models of cough: literature review and presentation of a novel cigarette smoke-enhanced cough model in the guinea-pig. Pulm Pharmacol Ther. 2007;20:325–33.CrossRefPubMed
7.
Lee L, Burki NK, Gerhardstein DC, Gu Q, Kou YR, Xu J. Airway irritation and cough evoked by inhaled cigarette smoke: role of neuronal nicotinic acetylcholine receptors. Pulm Pharmacol Ther. 2007;20:355–64.CrossRefPubMed
8.
Liu L, Zhu W, Zhang Z, Yang T, Grant A, Oxford G, et al. Nicotine inhibits voltage-dependent sodium channels and sensitizes vanilloid receptors. J Neurophysiol. 2004;91:1482–91.CrossRefPubMed
9.
Andre E, Campi B, Materazzi S, Trevisani M, Amadesi S, Massi D, et al. Cigarette smoke-induced neurogenic inflammation is mediated by alpha, beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest. 2008;118:2574–82.PubMed
10.
Kou YR, Kwong K, Lee L. Airway inflammation and hypersensitivity induced by chronic smoking. Resp Physiol Neurobiol. 2011;178:395–405.CrossRef
11.
Bai TR, Zhou D, Weir T, Walker B, Hegele R, Hayashi S, et al. Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol. 1995;269:L309–17.PubMed
12.
Dusser DJ, Djokic TD, Borson DB, Nadel JA. Cigarette smoke induces bronchoconstrictor hyperresponsiveness to substance P and inactivates airway neutral endopeptidase in the guinea pig. Possible role of free radicals. J Clin Invest. 1989;84:900–6.CrossRefPubMed
13.
Mackenzie AJ, Spina D, Page CP. Models used in the development of antitussive drugs. Drug Discov Today: Dis Models. 2004;1:297–302.CrossRef
14.
Dicpinigaitis PV. Current and future peripherally-acting antitussives. Respir Physiol Neurobiol. 2006;152:356–62.CrossRefPubMed
15.
Takahama K, Shirasaki T. Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007;3:8.CrossRefPubMed
16.
Morikawa T, Gallico L, Widdicombe J. Actions of moguisteine on cough and pulmonary rapidly adapting receptor activity in the guinea pig. Pharmacol Res. 1997;35:113–8.CrossRefPubMed
17.
Sant’Ambrogio G, Sant’Ambrogio FB. Action of moguisteine on the activity of tracheobronchial rapidly adapting receptors in the dog. Eur Respir J. 1998;11:339–44.CrossRefPubMed
18.
Shams H, Daffonchio L, Scheid P. Effects of levodropropizine on vagal afferent C-fibres in the cat. Br J Pharmacol. 1996;117:853–8.CrossRefPubMed
19.
Gao S, Li P, Yang H, Fang S, Su W. Antitussive effect of naringin on experimentally induced cough in Guinea pigs. Planta Med. 2011;77:16–21.CrossRefPubMed
20.
Fujimura M, Kamio Y, Hashimoto T, Matsuda T. Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy. J Asthma. 1994;31:463–72.CrossRefPubMed
21.
Luo YL, Zhang CC, Li PB, Nie YC, Wu H, Shen JG, et al. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. Int Immunopharmacol. 2012;13:301–7.CrossRefPubMed
22.
Barnabe R, Berni F, Clini V, Pirrelli M, Robuschi M, Rossi M, et al. The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough. Monaldi Arch Chest Dis. 1995;50:93–7.PubMed
23.
McLeod RL, Tulshian DB, Bolser DC, Varty GB, Baptista M, Fernandez X, et al. Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1] Octan-3-Ol) in preclinical models. Eur J Pharmacol. 2010;630:112–20.CrossRefPubMed
24.
Lomask J, Larson RA; 19, Cough/sneeze analyzer and method. US7104962 B2. 2006/9/12.
25.
26.
Mapp CE, Miotto D, Braccioni F, Saetta M, Turato G, Maestrelli P, et al. The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways. Am J Respir Crit Care Med. 2000;161:207–15.CrossRefPubMed
27.
Di Maria GU, Bellofiore S, Geppetti P. Regulation of airway neurogenic inflammation by neutral endopeptidase. Eur Respir J. 1998;12:1454–62.CrossRefPubMed
28.
Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G, Bongard JP, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss study on air pollution and lung diseases in adults, SAPALDIA team. Am J Respir Crit Care Med. 1994;150:1222–8.CrossRefPubMed
29.
Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:104S–15S.CrossRefPubMed
30.
Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256–76.CrossRefPubMed
31.
Joad JP, Munch PA, Bric JM, Evans SJ, Pinkerton KE, Chen CY, et al. Passive smoke effects on cough and airways in young guinea pigs: role of brainstem substance P. Am J Respir Crit Care Med. 2004;169:499–504.CrossRefPubMed
32.
Bonham AC, Kott KS, Joad JP. Sidestream smoke exposure enhances rapidly adapting receptor responses to substance P in young guinea pigs. J Appl Physiol. 1996;81:1715–22.PubMed
33.
Stevenson CS, Docx C, Webster R, Battram C, Hynx D, Giddings J, et al. Comprehensive gene expression profiling of rat lung reveals distinct acute and chronic responses to cigarette smoke inhalation. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1183–93.CrossRefPubMed
34.
Selman M, Cisneros-Lira J, Gaxiola M, Ramirez R, Kudlacz EM, Mitchell PG, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest. 2003;123:1633–41.CrossRefPubMed
35.
D’Hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J. 2005;26:204–13.CrossRefPubMed
36.
Churg A, Zhou S, Preobrazhenska O, Tai H, Wang R, Wright JL. Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am J Respir Cell Mol Biol. 2009;40:268–76.CrossRefPubMed
37.
Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:305–14.PubMed
38.
Smith J, Owen E, Earis J, Woodcock A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006;117:831–5.CrossRefPubMed
39.
Yamawaki I, Geppetti P, Bertrand C, Huber O, Daffonchio L, Omini C, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993;243:1–6.CrossRefPubMed
40.
Daffonchio L, Hernandez A, Melillo G, Clavenna G, Omini C. Effectiveness of levodropropizine against cigarette smoke-induced airway hyperreactivity: possible mechanism. Eur J Pharmacol. 1993;228:257–61.PubMed
41.
Chen YT, Zheng RL, Jia ZJ, Ju Y. Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med. 1990;9:19–21.CrossRefPubMed
Metadata
Title
Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure
Authors
Yu-long Luo
Pei-bo Li
Chen-chen Zhang
Yan-fang Zheng
Sheng Wang
Yi-chu Nie
Ke-jian Zhang
Wei-wei Su
Publication date
01-12-2013
Publisher
Springer Basel
Published in
Inflammation Research / Issue 12/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0664-6

Other articles of this Issue 12/2013

Inflammation Research 12/2013 Go to the issue

Original Research Paper

Serum amyloid A, phospholipase A2-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases

Original Research Paper

Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis

Original Research Paper

Direct comparison of laser Doppler flowmetry and laser Doppler imaging for assessment of experimentally-induced inflammation in human skin

Original Research Paper

Paeoniflorin inhibits inflammatory responses in mice with allergic contact dermatitis by regulating the balance between inflammatory and anti-inflammatory cytokines

Original Research Paper

Tonic stimulation of the pharyngeal mucosa causes pain and a reversible increase of inflammatory mediators

Original Research Paper

Inflammatory mediators of systemic inflammation in neonatal sepsis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits